TY - JOUR
T1 - CD80 Expressed by CD8 + T Cells Contributes to PD-L1-Induced Apoptosis of Activated CD8 + T Cells
AU - Rollins, Meagan R.
AU - Johnson, Rachel M
N1 - Publisher Copyright:
© 2017 Meagan R. Rollins and Rachel M. Gibbons Johnson.
PY - 2017
Y1 - 2017
N2 - Tumor cells are capable of limiting antitumor CD8 + T cell responses through their cell surface expression of PD-L1. In addition to PD-1 expressed by CD8 + T cells, PD-L1 also binds to CD80 expressed by CD8 + T cells. The influence of the PD-L1/CD80 interaction on CD8 + T cell function has not been fully characterized, so we sought to investigate the impact of the PD-L1/CD80 interaction on PD-L1-induced apoptosis of activated CD8 + T cells. We found that CD8 + T cells that lacked CD80 expression got activated to the same extent as wild-type CD8 + T cells, but when cultured with anti-CD3 and PD-L1/Fc protein, activated CD8 + T cells that lacked CD80 expression survived better than activated wild-type CD8 + T cells. These findings indicate that PD-L1 induces apoptosis in activated CD8 + T cells in part by signaling through CD80. Thus, in the design and implementation of checkpoint blockade therapies that target PD-L1, it is essential that both binding partners for PD-L1, PD-1, and CD80 are considered.
AB - Tumor cells are capable of limiting antitumor CD8 + T cell responses through their cell surface expression of PD-L1. In addition to PD-1 expressed by CD8 + T cells, PD-L1 also binds to CD80 expressed by CD8 + T cells. The influence of the PD-L1/CD80 interaction on CD8 + T cell function has not been fully characterized, so we sought to investigate the impact of the PD-L1/CD80 interaction on PD-L1-induced apoptosis of activated CD8 + T cells. We found that CD8 + T cells that lacked CD80 expression got activated to the same extent as wild-type CD8 + T cells, but when cultured with anti-CD3 and PD-L1/Fc protein, activated CD8 + T cells that lacked CD80 expression survived better than activated wild-type CD8 + T cells. These findings indicate that PD-L1 induces apoptosis in activated CD8 + T cells in part by signaling through CD80. Thus, in the design and implementation of checkpoint blockade therapies that target PD-L1, it is essential that both binding partners for PD-L1, PD-1, and CD80 are considered.
UR - http://www.scopus.com/inward/record.url?scp=85042475446&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85042475446&partnerID=8YFLogxK
U2 - 10.1155/2017/7659462
DO - 10.1155/2017/7659462
M3 - Article
C2 - 29181416
AN - SCOPUS:85042475446
SN - 2314-8861
VL - 2017
JO - Journal of Immunology Research
JF - Journal of Immunology Research
M1 - 7659462
ER -